MethylGene Inc. (MYG-TSX)
Interview with: Donald F. Corcoran, President and CEO
Business News, Financial News, Stocks, Money & Investment Ideas, CEO Interview
and Information on their novel therapeutics in cancer and infectious disease.

Cover Story

CEOCFO Current Issue

Cover Story Archives

Private Equity Review

CEOCFO Interview Index

Future Features

Analyst Interviews

Corporate Financials

Contact & Ordering

This is a printer friendly page!

MethylGene is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to fight cancer and infectious diseases



Healthcare
Biotechnology
(MYG-TSX)

MethylGene Inc.




Donald F. Corcoran
President and CEO

Interview conducted by:
Lynn Fosse, Senior Editor
CEOCFOinterviews.com
Mat 5, 2005

To order the complete May 5, 2005 Issue of CEOCFOinterviews.com left click below for our secure forms:

Purchase NOW!

There is a $5.00 charge for each current issue!
You will be emailed your Current Issue and an invoice for Credit Card payment!

disclaimers

Any reproduction or further distribution of this article without the express written consent of CEOCFOinterviews.com is prohibited.

“You are looking at a company that has renewable competencies. As we move drugs into clinical trials, we can put that research team of biologists and medicinal chemists onto a new project and move that forward; we are showing we can do that. We have two drugs in cancer clinical trials as we speak and we have good partnerships. With the HDAC opportunities outside of cancer, we have many possibilities available to us.” - Donald F. Corcoran

Newsflash!

To view Releases highlight & left click on the company name!